Skip to Content
Merck
CN
All Photos(1)

Documents

MABE333

Sigma-Aldrich

Anti-N-Myc Antibody, clone NCM II 100

clone NCM II 100, from mouse

Sign Into View Organizational & Contract Pricing

Synonym(s):
N-myc proto-oncogene protein, Class E basic helix-loop-helix protein 37, bHLHe37
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

NCM II 100, monoclonal

species reactivity

human

technique(s)

immunocytochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG1κ

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... MYCN(4613)

General description

The v-myc oncogene, initially identified in the MC29 avian retrovirus, causes myelocytomas, carcinomas, sarcomas and lymphomas, and belongs to a family of oncogenes conserved throughout evolution. In humans the family consists of five genes: c-myc, N-myc, R-myc, L-myc and B-myc. Amplification of the N-myc gene has been found in human neuroblastomas and cell lines. The extent of N-myc amplification correlates well with the stage of neuroblastoma disease. Immunological studies have shown that the human N-myc gene gives rise to at least two nuclear phosphoproteins that exhibit relatively short (30 min) half lives in vivo and exhibit DNA binding properties in vitro.

Immunogen

Recombinant protein corresponding to human N-Myc.

Application

Immunofluorescence Analysis: A representative lot from an independent laboratory detected N-Myc in IMR5 cells (Ikegaki, N., et al. (1986). 83(16):5929-5933.).

Immunoprecipitation Analysis: A representative lot from an independent laboratory immunoprecipitated N-Myc in IP (Brondyk, W. H., et al. (1991). 6(7):1269-1276.).
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors
Use Anti-N-Myc Antibody, clone NCM II 100 (mouse monoclonal antibody) validated in WB, IP, ICC to detect N-Myc also known as N-myc proto-oncogene protein, Class E basic helix-loop-helix protein 37, bHLHe37.

Quality

Evaluated by Western Blot in IMR-32 cell lysate.

Western Blot Analysis: 0.5 µg/mL of this antibody detected N-Myc in 10 µg of IMR-32 cell lysate.

Target description

~55 kDa observed. Uniprot describes a molecular weight at ~50 kDa Uniprot states that this protein may be phosphorylated.

Physical form

Format: Purified
Protein G Purified
Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Analysis Note

Control
IMR-32 cell lysate

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Annie Beaudry et al.
Scientific reports, 13(1), 16443-16443 (2023-10-01)
Neuroblastoma, the most common type of pediatric extracranial solid tumor, causes 10% of childhood cancer deaths. Despite intensive multimodal treatment, the outcomes of high-risk neuroblastoma remain poor. We urgently need to develop new therapies with safe long-term toxicity profiles for
Felix Schmitt-Hoffner et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(29), 3217-3228 (2021-06-11)
Clinical outcomes of patients with neuroblastoma range from spontaneous tumor regression to fatality. Hence, understanding the mechanisms that cause tumor progression is crucial for the treatment of patients. In this study, we show that FOXR2 activation identifies a subset of
Patrick Sin-Chan et al.
Cancer cell, 36(1), 51-67 (2019-07-10)
Embryonal tumors with multilayered rosettes (ETMRs) are highly lethal infant brain cancers with characteristic amplification of Chr19q13.41 miRNA cluster (C19MC) and enrichment of pluripotency factor LIN28A. Here we investigated C19MC oncogenic mechanisms and discovered a C19MC-LIN28A-MYCN circuit fueled by multiple

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service